Recap: Inovio Pharmaceuticals Q1 Earnings

Shares of Inovio Pharmaceuticals INO decreased in after-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share decreased 3.85% over the past year to ($0.27), which missed the estimate of ($0.18).

Revenue of $371,120 declined by 72.03% from the same period last year, which missed the estimate of $850,000.

Looking Ahead

Inovio Pharmaceuticals hasn't issued any earnings guidance for the time being.

Revenue guidance hasn't been issued by the company for now.

Conference Call Details

Date: May 10, 2021

Time: 04:30 PM

ET Webcast URL: https://www.webcaster4.com/Webcast/Page/2021/41181

Recent Stock Performance

52-week high: $33.79

Company's 52-week low was at $6.24

Price action over last quarter: down 33.23%

Company Profile

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!